For example, a Nrf2 activator Bardoxolone-methyl was used for treating Alport’s syndrome diseases and diabetic kidney disease, and it was shown to exert ideal efficacy in the clinical trial. The gene discussed is NFE2L2; the disease is diabetic kidney disease.